U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. CPG Sec. 455.100 Inert Glandular Preparations *(OTC)*, Inadequate Full Disclosure and Claims
  1. Search for FDA Guidance Documents

COMPLIANCE POLICY GUIDE (CPG)

CPG Sec. 455.100 Inert Glandular Preparations *(OTC)*, Inadequate Full Disclosure and Claims May 1987

Final
Docket Number:
None found
Issued by:
Guidance Issuing Office
Center for Drug Evaluation and Research

BACKGROUND:

*When it was discovered that some glands produce hormones, a variety of glandular products were placed on the market for OTC medicinal use. Many of these commercial glandular preparations contained very little hormonal activity.

POLICY:

Our policy on inert glandular preparations is expressed in 21 CFR 201.300. It is our policy that inert glandular preparations intended for medicinal use are not exempt from Section 502(f)(1), that they bear adequate directions for use including indications for use and any such representations offering these articles for use as drugs would be false and misleading, and cause such articles to be unapproved new drugs*.

REGULATORY ACTION GUIDANCE:

The following represents criteria for recommending legal action to the *Division of Drug Labeling Compliance, HFD-310*.

Any desiccated whole or aqueous extracts of the following animal glands:

Adrena Orchic
Adrenal Cortex Parathyroid
Brain Parotid
Duodenum Pineal
Embryo Pituitary
Heart Placenta
Kidney Prostate
Liver Spleen
Lymph Stomach
Mammary Thymus
Ovary *Thyroid*

and

Such inert glandular preparation is offered for *OTC* drug use, other than, use limited to vitamin content in the case of liver preparations; use limited to intrinsic factor content in the case of stomach and duodenum, and parenteral use in the case of parathyroid.

*Material between asterisks is new or revised*

Issued: 10/1/80
Revised: 5/22/87

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: None found.

Back to Top